非酒精性脂肪性肝病的靶点发现与药物研发进展

Progress in target discovery and drug development for non⁃alcohol fatty liver disease

非酒精性脂肪性肝病(NAFLD)是一种常见的慢性代谢性疾病,其主要特征为肝脏脂肪堆积。NAFLD的发生和发展与多种代谢异常相关,包括肥胖、糖尿病和高血脂等。由于其在全球范围内的高发病率和危险性,NAFLD已成为公共卫生领域的一个重要问题。然而到目前为止,NAFLD的治疗方法非常有限,至今欧美和我国均无相关药物获批上市,且近年来新药临床试验并不顺利。本文综述了NAFLD治疗靶点、新药临床研究进展及治疗新途径,此外总结了NASH临床试验高失败率的原因并提出了相应解决方案,旨在为新药研发提供思路与参考。

Non⁃alcoholic fatty liver disease(NAFLD)is a common chronic metabolic disease characterized by the accumulation of fat in the liver.The onset and progression of NAFLD are associated with a variety of metabolic abnormalities,including obesity,diabetes mellitus,and hyperlipidemia.Due to its high prevalence and risk worldwide,NAFLD has become an important issue in public health.However,to date,treatments for NAFLD are very limited,with no relevant drugs approved for marketing in Europe,America,or China and clinical trials of new drugs have gained no progress in recent years.This paper reviews the therapeutic targets,clinical research progress of new drugs,and new treatment strategies for NAFLD,in addition to summarizing the reasons for the high failure rate of NASH clinical trials and proposing corresponding solutions,aiming at providing ideas and reference for new drug development.